药物涂层球囊治疗冠状动脉大血管原位病变的疗效与安全性
该回顾性研究纳入102例患者共104处参考管腔直径>2.8 mm的冠状动脉原位病变,接受药物涂层球囊(DCB)治疗。随访造影晚期管腔丢失为(0.01±0.52)mm,12个月靶病变血运重建率和主要心血管不良事件率均为3.9%,无死亡、心肌梗死及靶病变血栓形成,提示DCB治疗大血管原位病变安全有效。
要点
- DCB治疗参考管腔直径>2.8 mm的冠状动脉原位病变,随访晚期管腔丢失仅(0.01±0.52)mm。
- 12个月靶病变血运重建率与主要心血管不良事件率均为3.9%,无死亡、心肌梗死及靶病变血栓。
- 6例(5.9%)因严重冠状动脉夹层行补救性药物洗脱支架治疗。
核心结论
- DCB治疗冠状动脉大血管原位病变安全、有效。
研究设计与样本
- 回顾性分析2015年5月至2017年7月单中心102例患者共104处参考管腔直径>2.8 mm的冠状动脉原位病变,均接受DCB治疗。
- 82例(80.4%)患者在术后(8.1±1.7)个月行随访冠状动脉造影及定量冠状动脉造影分析。
主要发现
- 104处病变中98处单独使用DCB,6例(5.9%)因严重冠状动脉夹层行补救性药物洗脱支架治疗。
- 2例(2.0%)患者在住院期间因急性缺血事件驱动行再次血运重建。
- 术中65.4%(68/104)病变使用切割球囊,26.0%(27/104)病变使用棘突球囊。
- 病变长度为(12.57±3.58)mm,DCB长度为(19.87±4.55)mm,随访晚期管腔丢失为(0.01±0.52)mm。
- 12个月随访靶病变血运重建率和主要心血管不良事件率均为3.9%(4/102),无死亡、心肌梗死及靶病变血栓形成。
临床怎么用
- 对于参考管腔直径>2.8 mm的冠状动脉原位病变,DCB可作为治疗选择之一。
- 术中可根据病变特点选用切割球囊或棘突球囊进行预处理。
- 出现严重冠状动脉夹层时,需及时行补救性药物洗脱支架治疗。
局限性
- 本研究为单中心回顾性分析,样本量有限。
- 随访造影率仅为80.4%(82/102),部分患者未行造影随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of drug-coated balloons (DCB) for de novo large coronary vessels. Methods: One hundred and two patients were retrospectively enrolled in this study, there were 104 lesions with the reference lumen diameter of target vessel more than 2.8 mm and patients were treated with DCB in de novo lesions during May 2015 and July 2017 in our center. Coronary artery angiography and quantitative coronary angiography were performed in 82 (80.4%) patients at follow up period ((8.1±1.7) months post procedure). The endpoints were late lumen loss (LLL) at follow up,and major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) and stent or target lesion thrombosis at 12 months post procedure. Results: Ninety-eight lesions were treated with DCB only, 6 (5.9%) bailout drug-eluting stent (DES) were used because of severe coronary dissection, 2 patients (2.0%) received revascularization driven by acute ischemic events during hospitalization. Cutting balloons and NSE balloons were used in 65.4% (68/104) and 26.0% (27/104) lesions. The lesion length was (12.57±3.58) mm and the DCB length was (19.87±4.55) mm. The late lumen loss was (0.01±0.52) mm during angiographic follow up. The TLR rate and overall MACE rate was 3.9% (4/102) and 3.9% (4/102) and there was no death,MI and target lesion thrombosis at 12 months follow up. Conclusion: DCB treatment for de novo large coronary vessels is effective and safe. 目的: 观察药物包被球囊(DCB)治疗冠状动脉大血管原位病变的疗效。 方法: 回顾性分析2015年5月至2017年7月郑州大学第一附属医院心内科冠状动脉病变血管>2.8 mm且接受DCB治疗的原位病变患者102例,共104处病变,在术后9个月有82例(80.4%)患者行随访冠状动脉造影检查和冠状动脉造影定量分析。观察终点是随访时冠状动脉造影的晚期管腔丢失和主要心血管不良事件,包括心原性死亡、心肌梗死、靶病变血运重建、靶病变或支架内血栓形成。 结果: 104处病变中98处病变单独置入DCB,6例(5.9%)患者因严重冠状动脉夹层进行了补救性支架治疗。2例(2.0%)患者在住院期间出现急性缺血事件驱动的再次血运重建。术中65.4%(68/104)的病变使用切割球囊,26.0%(27/104)的病变使用了棘突球囊。病变长度为(12.57±3.58)mm,DCB长度为(19.87±4.55)mm,随访时晚期管腔丢失为(0.01±0.52)mm。随访期内,靶病变血运重建率和主要心血管不良事件发生率分别为3.9%(4/102)和3.9%(4/102),无死亡、心肌梗死及靶病变血栓形成。 结论: 提示DCB治疗冠状动脉大血管原位病变安全、有效。.
引用
- Qiu J, Han ZY, Wang X, et al. [Outcomes of patients treated with drug-coated balloons for de novo large coronary vessels]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019. PMID: 31262129. doi:10.3760/cma.j.issn.0253-3758.2019.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。